Depression, the Autonomic Nervous System, and Coronary Heart Disease

Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Psychosomatic Medicine (Impact Factor: 3.47). 05/2005; 67 Suppl 1(supplement 1):S29-33. DOI: 10.1097/01.psy.0000162254.61556.d5
Source: PubMed

ABSTRACT Depression is a risk factor for medical morbidity and mortality in patients with coronary heart disease (CHD). Dysregulation of the autonomic nervous system (ANS) may explain why depressed patients are at increased risk. Studies of medically well, depressed psychiatric patients have found elevated levels of plasma catecholamines and other markers of altered ANS function compared with controls. Studies of depressed patients with CHD have also uncovered evidence of ANS dysfunction, including elevated heart rate, low heart rate variability, exaggerated heart rate responses to physical stressors, high variability in ventricular repolarization, and low baroreceptor sensitivity. All of these indicators of ANS dysfunction have been associated with increased risks of mortality and cardiac morbidity in patients with CHD. Further research is needed to determine whether ANS dysfunction mediates the effects of depression on the course and outcome of CHD, and to develop clinical interventions that improve cardiovascular autonomic regulation while relieving depression in patients with CHD.
ANS = autonomic nervous system; CHD = coronary heart disease; HRV = heart rate variability; MI = myocardial infarction; NE = norepinephrine; SNS = sympathetic nervous system.

Download full-text


Available from: Robert M Carney, Sep 25, 2015
1 Follower
656 Reads
  • Source
    • "was associated with emotion-focused coping and external health locus of control in UC and CD patients (Pellissier et al., 2010). The autonomic nervous system (ANS) plays a crucial role in pathogenesis of both IBD (Taylor and Keely, 2007) and depression (Carney et al., 2005; Jarrett et al., 2003). We have previously shown that vagal nerve integrity is an important protective factor in experimental colitis (Ghia et al., 2007, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Crohn's disease (CD) is associated with increased psychiatric co-morbidities. Nitric oxide (NO) is implicated in inflammation and tissue injury in CD, and it may also play a central role in pathogenesis of the accompanying behavioral despair. This study investigated the role of the NO pathway in behavioral despair associated with a mouse model of CD. Colitis was induced by intrarectal (i.r.) injection of 2, 4, 6-trinitrobenzenesulfonic acid (10mg TNBS in 50% ethanol). Forced swimming test (FST), pharmacological studies and tissues collection were performed 72hours following TNBS administration. To address a possible inflammatory origin for the behavioral despair following colitis induction, tumor necrosis factor-alpha (TNF-α) level was measured in both the hippocampal and colonic tissue samples. In parallel, hippocampal inducible nitric oxide synthase (iNOS) and nitrite level were evaluated. Pharmacological studies targeting the NO pathway was performed 30-60 mins before behavioral test. Colitis was confirmed by increased colonic TNF-α level and microscopic score. Colitic mice demonstrated a significantly higher immobility time in the FST associated to a significant increase of hippocampal TNF-α, iNOS expression and nitrite content. Acute NOS inhibition using either Nω-nitro-L-arginine methyl ester (a non-specific NOS inhibitor) or aminoguanidine hydrochloride (a specific iNOS inhibitor) decreased the immobility time in colitic groups. Moreover, acute treatment with both NOS inhibitors decreased the TNF-α level and nitrite content in the hippocampal samples. This study suggests that the NO pathway may be involved in the behavioral effects in the mouse TNBS model of CD. These findings endow new insights into the gut-brain communication during the development of colonic inflammation, which may ultimately lead to improved therapeutic strategies to combat behavior changes associated with gastrointestinal disorders. Copyright © 2015. Published by Elsevier Inc.
    Progress in Neuro-Psychopharmacology and Biological Psychiatry 08/2015; 64. DOI:10.1016/j.pnpbp.2015.08.004 · 3.69 Impact Factor
  • Source
    • "The relative contribution of the sympathetic and parasympathetic nervous systems to depression-related altered cardiac reactivity as a risk factor for cardiovascular diseases is still debated (Carney et al., 2005). Nonetheless, the current findings suggest that depression is more likely to be associated with reduced cardiac vagal modulation rather than excessive sympathetic activity on heart. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to examine the influence of depression on heart rate and heart rate variability (HRV) during emotional imagery in patients after cardiac surgery. Based on the scores of the Center for Epidemiological Studies of Depression (CES-D) scale, 28 patients after cardiac surgery were assigned either to the group with depression (CES-D scores≥16; N=14) or the one without depression (CES-D scores<16; N=14). Each patient completed a rest period and an emotional imagery including pleasant, neutral and unpleasant scripts. Inter-beat intervals (IBIs) and HRV were measured during the entire protocol. Compared to nondepressed patients, those with depression had greater reductions in high frequency expressed in normalized units (HF n.u.) during the imaging of the unpleasant script (p=.003, Cohen's d=1.34). Moreover, HF n.u. were lower during the imaging of the unpleasant script than the pleasant one in depressed patients only (p=.020, Cohen's d=0.55). CES-D scores were also inversely correlated with residualized changes in IBIs (r=-.38, p=.045) and HF n.u. (r=-.49, p=.008) from rest to the imaging of the unpleasant script. The relationship between depression and increased vagal withdrawal during unpleasant emotional imagery extends to patients after cardiac surgery. The present study suggests that increased vagal withdrawal to negative emotions in patients after cardiac surgery may mediate the conferral of cardiac risk by depression. Copyright © 2014 Elsevier B.V. All rights reserved.
    Autonomic neuroscience: basic & clinical 02/2015; 189. DOI:10.1016/j.autneu.2015.02.002 · 1.56 Impact Factor
  • Source
    • "Besides the overwhelming data on neurochemical and behavioral changes in the OBX animal (Song and Leonard, 2005), several physiological, immunological (Leonard, 2014; Song and Leonard, 2005) and autonomic parameters are also affected whereas recently also disturbances in gut functions were found in OBX mice (Park et al., 2013) likely due to activation of the HPA-axis. In light of autonomic dysfunction in depression (Carney et al., 2005), an important aspect of OBX animals appears an inability to adapt to stress, which might be due to amygdaloid disinhibition (Kelly et al., 1997; Wrynn et al., 2000). Vinkers et al. (2009a) found indeed stable and persistent changes in nocturnal locomotor activity, body temperature, heart rate and heart rate variability. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The neurotransmitter serotonin is an evolutionary ancient molecule that has remarkable modulatory effects in almost all central nervous system integrative functions, such as mood, anxiety, stress, aggression, feeding, cognition and sexual behavior. After given a short outline of the serotonergic system (anatomy, receptors, transporter) the author's contributions over the last 40 years in the role of serotonin in depression, aggression, anxiety, stress and sexual behavior is outlined. Each area delineates the work performed on animal model development, drug discovery and development. Most of the research described has started from an industrial perspective, aimed at developing animals models for psychiatric diseases and leading to putative new innovative psychotropic drugs, like in the cases of the SSRI fluvoxamine, the serenic eltoprazine and the anxiolytic flesinoxan. Later research mainly focused on developing translational animal models for psychiatric diseases and implicating them in the search for mechanisms involved in normal and diseased brains and finding new concepts for appropriate drugs. Copyright © 2014. Published by Elsevier B.V.
    European Journal of Pharmacology 11/2014; 753. DOI:10.1016/j.ejphar.2014.10.031 · 2.53 Impact Factor
Show more